Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced ...
MedPage Today on MSN
Pre-existing fatigue tied to worse toxicity from systemic cancer therapy
Higher levels of pre-existing fatigue in cancer patients correlated with greater risk of experiencing severe or worse toxic ...
Natera (NTRA) announced the publication of findings from the randomized, phase III CALGB/SWOG 80702 study in JAMA Oncology. This publication ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in ...
Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...
AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 ...
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback